David M. Rubenstein - 06 May 2026 Form 4 Insider Report for Moderna, Inc. (MRNA)

Reporting relationship: Director
Issuer ticker: MRNA
Reported as of: 06 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 08 May 2026, 17:07:55 UTC
Prior SEC filing: 04 May 2026
Source filing: View source filing
Reporting owner signature: /s/ James Dillon, As Attorney-in-Fact

Key filing fact

David M. Rubenstein filed Form 4 for Moderna, Inc. (MRNA) on 08 May 2026.

Key facts

This page summarizes David M. Rubenstein's Form 4 filing for Moderna, Inc. (MRNA).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 08 May 2026, 17:07.

Change

Previous filing in this sequence was filed on 04 May 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001543895 Primary reporting owner

Rubenstein David M.

Relationship: Director
Address: C/O MODERNA, INC., 325 BINNEY STREET, CAMBRIDGE
Signature: /s/ James Dillon, As Attorney-in-Fact
Signature date: 08 May 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MRNA transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +9,681
Change %
Price: $0.000000^*
Shares after: 9,681
Date: 06 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 9,681
Exercise price: $48.79
Footnotes: F1

MRNA transaction Derivative

Restricted Stock Units

Award

Transaction value
Shares: +2,092
Change %
Price: $0.000000^*
Shares after: 2,092
Date: 06 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 2,092
Exercise price
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

This option will become fully vested and exercisable on the earlier of May 6, 2027, or Moderna's next Annual Meeting of Shareholders, subject to the recipient's continued service.

Footnote F2

Restricted stock units convert into common stock on a one-for-one basis.

Footnote F3

The shares subject to this restricted stock unit award will vest in full on the earlier of May 6, 2027, or Moderna's next Annual Meeting of Shareholders, subject to the recipient's continued service.